This observation is counter to that of Cole et al. [20] who identified neuroblastoma as a potential therapeutic target for Chk1 inhibition and that sensitivity to Chk1 inhibition by either siRNA or small molecules correlated with Chk1 S296 phosphorylation. Here, CHEK1 is linked to neuroblastoma.